IN2014DN09571A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09571A
IN2014DN09571A IN9571DEN2014A IN2014DN09571A IN 2014DN09571 A IN2014DN09571 A IN 2014DN09571A IN 9571DEN2014 A IN9571DEN2014 A IN 9571DEN2014A IN 2014DN09571 A IN2014DN09571 A IN 2014DN09571A
Authority
IN
India
Prior art keywords
agonist
active ingredients
pharmaceutical formulation
special
constituent
Prior art date
Application number
Other languages
English (en)
Inventor
John Bondo Hansen
Mikael S Thomsen
Jens D Mikkelsen
Peter Gudmund Nielsen
Mads Kreilgaard
Original Assignee
Contera Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2012/050190 external-priority patent/WO2012163365A1/fr
Application filed by Contera Pharma Aps filed Critical Contera Pharma Aps
Publication of IN2014DN09571A publication Critical patent/IN2014DN09571A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN9571DEN2014 2012-04-18 2013-04-18 IN2014DN09571A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201270196 2012-04-18
PCT/DK2012/050190 WO2012163365A1 (fr) 2011-06-01 2012-06-01 Combinaisons d'agonistes de récepteur de sérotonine pour le traitement de troubles du mouvement
DKPA201270755 2012-12-04
PCT/DK2013/050111 WO2013156035A1 (fr) 2012-04-18 2013-04-18 Formulation pharmaceutique disponible pour une administration par voie orale appropriée pour une gestion améliorée de troubles du mouvement

Publications (1)

Publication Number Publication Date
IN2014DN09571A true IN2014DN09571A (fr) 2015-07-17

Family

ID=49382938

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9571DEN2014 IN2014DN09571A (fr) 2012-04-18 2013-04-18

Country Status (24)

Country Link
US (1) US10561618B2 (fr)
EP (1) EP2838517B1 (fr)
JP (1) JP6216768B2 (fr)
KR (1) KR102104635B1 (fr)
CN (1) CN104411301B (fr)
AU (1) AU2013248685B2 (fr)
BR (1) BR112014025907B1 (fr)
CA (1) CA2870123C (fr)
DK (1) DK2838517T3 (fr)
ES (1) ES2654787T3 (fr)
HK (1) HK1207285A1 (fr)
HU (1) HUE037732T2 (fr)
IL (1) IL235000B (fr)
IN (1) IN2014DN09571A (fr)
MX (1) MX361372B (fr)
MY (1) MY169068A (fr)
NO (1) NO2838517T3 (fr)
NZ (1) NZ700474A (fr)
PH (1) PH12014502331B1 (fr)
PL (1) PL2838517T3 (fr)
PT (1) PT2838517T (fr)
RU (1) RU2670272C2 (fr)
SG (1) SG11201406690SA (fr)
WO (1) WO2013156035A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170021848A (ko) * 2014-06-26 2017-02-28 콘테라 파르마 에이피에스 부스피론 대사물의 용도
US10548885B2 (en) * 2014-07-09 2020-02-04 Pierre Fabre Medicament Method for treating movement disorders with befiradol
EP3253753A4 (fr) 2015-01-20 2018-06-27 Xoc Pharmaceuticals, Inc Composés d'ergoline et leurs utilisations
BR112019025420A2 (pt) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. Compostos policíclicos e usos destes
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
US11559525B2 (en) 2019-04-26 2023-01-24 Sumitomo Pharma Co., Ltd. Therapeutic drug for dyskinesia
US10758535B1 (en) * 2019-04-26 2020-09-01 Sumitomo Dainippon Pharma Co., Ltd. Therapeutic drug for dyskinesia
US11364225B2 (en) 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
CN116113402A (zh) 2020-08-31 2023-05-12 住友制药株式会社 帕金森病的运动并发症治疗药

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4182763A (en) 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
DE19775091I2 (de) 1990-06-07 2007-05-24 Astrazeneca Ab Therapeutische heterocyclische Verbindungen
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
GB9209882D0 (en) 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
US5484788A (en) 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
ES2292636T3 (es) 2000-11-29 2008-03-16 Eli Lilly And Company 1-(2-m-metanosulfanomidofeniletil)-4-(m-trifluorometilfenil)piper.
WO2002053139A2 (fr) 2001-01-05 2002-07-11 Eli Lilly And Company Combinaison d'antagoniste de recepteur d'acide amine excitateur et d'agoniste 5-ht1f : methode de traitement de troubles neurologiques
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
CN1520286B (zh) * 2001-07-04 2010-12-01 太阳医药工业有限公司 胃滞留控制药物释出系统
ES2262840T3 (es) * 2001-09-19 2006-12-01 Merck Patent Gmbh Nuevo uso de los aminometil cromanos substituidos.
JP2007508249A (ja) * 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ フィブラートとスタチンを含む固体剤型
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
DE10353657A1 (de) 2003-11-17 2005-06-23 Merck Patent Gmbh Indolderivate
US20070173536A1 (en) 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
EP1771158A4 (fr) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Comprimé pour distribution par impulsion
JP2008512436A (ja) * 2004-09-07 2008-04-24 ファイザー・インク 片頭痛治療用の５−ＨＴ（１）受容体アゴニストとα２δリガンドの組み合わせ
EP1833467B1 (fr) * 2004-12-20 2016-08-03 Collegium Pharmaceutical, Inc. Compositions pharmaceutiques destinees a des troubles du sommeil
ATE466853T1 (de) * 2005-01-18 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
MX2007012374A (es) * 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
WO2007129329A2 (fr) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Préparation pharmaceutique à libération prolongée comprenant du chlorhydrate de venlafaxine
EP2026813A2 (fr) * 2006-05-09 2009-02-25 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
JP2009539942A (ja) 2006-06-16 2009-11-19 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ビフェプルノックス及びｌ−ｄｏｐａを含む組み合わせ製剤
US20080069874A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis
WO2008047839A1 (fr) * 2006-10-19 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. Agoniste du récepteur de la 5-ht1a
JP5269894B2 (ja) 2007-06-27 2013-08-21 ハンミ ファーム． シーオー．， エルティーディー． 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置
EP2105130A1 (fr) * 2008-03-25 2009-09-30 Ratiopharm GmbH Formule pharmaceutique et son procédé de fabrication
EP2317996A1 (fr) 2008-06-24 2011-05-11 Anders Björklund Eltoprazine pour la suppression de dyskinésies induites par le l-dopa
KR20110071008A (ko) 2008-10-14 2011-06-27 맥닐 에이비 다중 부분 경구내 투여량 형태 및 그의 용도
MX2011007817A (es) 2009-01-23 2011-09-21 A F S P A Aziende Chimichi Riunite Angelini Francesco A C R Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
SG181896A1 (en) 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
JP5907975B2 (ja) 2010-10-15 2016-04-26 コンテラ ファーマ アンパルトセルスカブＣｏｎｔｅｒａ Ｐｈａｒｍａ Ａｐｓ 運動障害の治療のためのセロトニン受容体アゴニストの組み合わせ
US20140221385A1 (en) 2011-06-01 2014-08-07 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders

Also Published As

Publication number Publication date
EP2838517A1 (fr) 2015-02-25
MX361372B (es) 2018-12-05
MY169068A (en) 2019-02-12
BR112014025907B1 (pt) 2023-02-14
AU2013248685A1 (en) 2014-10-16
KR20140146207A (ko) 2014-12-24
EP2838517B1 (fr) 2017-10-18
JP2015514727A (ja) 2015-05-21
HK1207285A1 (en) 2016-01-29
DK2838517T3 (en) 2018-01-15
MX2014012408A (es) 2014-12-10
RU2670272C2 (ru) 2018-10-22
US20150104506A1 (en) 2015-04-16
HUE037732T2 (hu) 2018-09-28
SG11201406690SA (en) 2014-11-27
ES2654787T3 (es) 2018-02-15
IL235000B (en) 2018-01-31
NZ700474A (en) 2016-10-28
NO2838517T3 (fr) 2018-03-17
WO2013156035A1 (fr) 2013-10-24
CA2870123C (fr) 2021-02-23
PL2838517T3 (pl) 2018-03-30
AU2013248685B2 (en) 2017-07-27
JP6216768B2 (ja) 2017-10-18
CN104411301A (zh) 2015-03-11
PH12014502331A1 (en) 2014-12-22
US10561618B2 (en) 2020-02-18
CN104411301B (zh) 2018-02-06
PH12014502331B1 (en) 2014-12-22
BR112014025907A2 (pt) 2017-06-20
RU2014145944A (ru) 2016-06-10
KR102104635B1 (ko) 2020-04-27
PT2838517T (pt) 2018-01-04
CA2870123A1 (fr) 2013-10-24

Similar Documents

Publication Publication Date Title
IN2014DN09571A (fr)
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
PH12019501937A1 (en) Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
MX355915B (es) Moduladores del receptor de androgenos y usos de los mismos.
TN2015000244A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201792595A1 (ru) Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела
BR112013030939A2 (pt) derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
PH12017501736A1 (en) Indole derivatives
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
JP2015520154A5 (fr)
TN2013000429A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity